Prestige Consumer Healthcare Inc. Investigation - PBH

Company
Prestige Consumer Healthcare Inc. (NYSE: PBH)

Learn more about the Prestige Consumer Healthcare Inc. Investigation

Required Field

Required Field

Required Field

  • $1 - $1,000
  • $1001 - $10,000
  • $10,001 - $25,000
  • $25,001 - $50,000
  • $50,001 - $100,000
  • $100,001 - $250,000
  • $250,001 - $500,000
  • $500,000+

There is no cost or obligation for you to submit.

The submission of this form does not create an attorney-client relationship.

Please Upload related files below

Add Transactions

Purchases

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Purchases

Sales

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Sales

Please input at least 1 transaction or press "skip for now" button below

Please fill in all the fields for your transaction or press "skip for now" button below

Alternatively, you may upload your transactions below or e-mail them to [email protected]

Upload Your Stock Tickers

Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.

Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.

Skip

Prestige Consumer Healthcare Inc. Investigation Details

During the Q3 FY 2026 earnings call, CEO Ron Lombardi stated that Prestige Consumer Healthcare anticipated a 57% adjusted gross margin in Q4. Management further projected projected free cash flow of $245 million or more for the full year alongside an adjusted EPS of $4.54. When Q4 results were reported, adjusted gross margin came in at approximately 55.4%, full-year free cash flow totaled $228 million, and adjusted diluted EPS was only 4.38; all three missed Prestige’s internal projections. Separately, Prestige Consumer Healthcare completed a $150 million acquisition of Australian skin-care firm LaCorium during the period. The acquisition was not discussed on the Q3 earnings call and was absent from the forward guidance framework presented to investors. PBH shares declined sharply following the Q4 disclosure.

Get Started